Kumquat Biosciences Inc. has described compounds acting as GTPase KRAS wild-type and mutant inhibitors reported to be useful for the treatment of cancer.
Evotec International GmbH has divulged NLRP3 inflammasome inhibitors reported to be useful for the treatment of asthma, cryopyrin-associated periodic syndromes, hypertension, Alzheimer’s disease, rheumatoid arthritis, diabetes, multiple sclerosis and Parkinson’s disease.
Beijing Tide Pharmaceutical Co. Ltd. has identified protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer and myelofibrosis.
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. and Nanjing Chia Tai Tianqing Pharmaceutical Co. Ltd. have announced IND clearance by China’s National Medical Products Administration (NMPA) for NTB-003 (formerly BCG-009) for thyroid eye disease.
Human adenovirus may cause severe infections in both immunosuppressed and immunocompetent individuals and there is no specific approved therapy for it to date. The incidence may be about 50%-60% in immunocompromised subjects, with mortality rates around 80% in patients with disseminated infections.
Chronic pain is a constant challenge to around 20% of the global population, and treatments to mitigate such pain often cause unacceptable side effects because the receptors and signaling pathways involved in pain sensing also drive necessary processes in the heart, lungs and liver. Opioid analgesics can be effective against chronic pain, but they can lead to tolerance and addiction.